 |
50 Diseases |  |
65 Trials |
|
65 Trials |  |
4287 News |  |
| «12...3738394041424344454647...4950» |
- |||| Enrollment open, Tumor mutational burden, BRCA Biomarker, PARP Biomarker, PD(L)-1 Biomarker: Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (clinicaltrials.gov) - Mar 16, 2018
P2, N=720, Recruiting, Sponsor: Canadian Cancer Trials Group
Not yet recruiting --> Recruiting
- | Gazyva (obinutuzumab) / Roche, Biogen, Zelboraf (vemurafenib) / Roche
Trial initiation date: A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia (clinicaltrials.gov) - Mar 8, 2018
P2, N=28, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Not yet recruiting --> Recruiting Initiation date: Feb 2018 --> Feb 2018
- | Gazyva (obinutuzumab) / Roche, Biogen, Zelboraf (vemurafenib) / Roche
Trial initiation date: A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia (clinicaltrials.gov) - Mar 3, 2018
P2, N=28, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Initiation date: Feb 2018 --> Feb 2018 Initiation date: Jan 2018 --> Feb 2018
- | Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Enrollment open, Surgery: RadioCoBRIM: Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases (clinicaltrials.gov) - Feb 27, 2018
P2, N=32, Recruiting, Sponsor: Technische Universit
Initiation date: Jan 2018 --> Feb 2018 Not yet recruiting --> Recruiting
- Zelboraf (vemurafenib) / Roche
Trial completion date, Trial primary completion date: Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study (clinicaltrials.gov) - Feb 26, 2018
P=N/A, N=12, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: May 2018 --> May 2019 | Trial completion date: May 2018 --> May 2019
- || Biomarker, Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Feb 23, 2018
P2, N=1400, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: May 2018 --> May 2019 | Trial completion date: May 2018 --> May 2019 Trial primary completion date: Oct 2020 --> May 2017
- |||| Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, Metastases: IMspire150: A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma (clinicaltrials.gov) - Feb 22, 2018
P3, N=500, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Oct 2020 --> May 2017 Trial primary completion date: Jul 2019 --> Oct 2019 | Trial completion date: Jul 2019 --> Jul 2023
- ||| Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Enrollment closed, Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy, Metastases: GEM-01-15: Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma (clinicaltrials.gov) - Feb 19, 2018
P2, N=70, Active, not recruiting, Sponsor: Grupo Espa
Trial primary completion date: Jul 2019 --> Oct 2019 | Trial completion date: Jul 2019 --> Jul 2023 Recruiting --> Active, not recruiting | N=116 --> 70 | Trial primary completion date: Dec 2018 --> Sep 2019 | Trial completion date: Dec 2018 --> Sep 2019 | Initiation date: Jun 2015 --> Jun 2015
- | Journal: Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model. (Pubmed Central) - Feb 17, 2018
The PDOX model thus helped identify the very-high efficacy of TRA against the melanoma PDOX and is a promising drug for this patient. These results demonstrate the powerful precision of the PDOX model for cancer therapy, not achievable by genomic analysis alone.
- || Zelboraf (vemurafenib) / Roche
Trial completion date, Trial primary completion date: An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol (clinicaltrials.gov) - Feb 14, 2018
P4, N=450, Recruiting, Sponsor: Hoffmann-La Roche
These results demonstrate the powerful precision of the PDOX model for cancer therapy, not achievable by genomic analysis alone. Trial primary completion date: Feb 2019 --> Dec 2019 | Trial completion date: Feb 2019 --> Jun 2020
- Zelboraf (vemurafenib) / Roche
Trial completion date, Trial primary completion date: A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants (clinicaltrials.gov) - Feb 13, 2018
P1, N=8, Completed, Sponsor: Hoffmann-La Roche
Trial primary completion date: Feb 2019 --> Dec 2019 | Trial completion date: Feb 2019 --> Jun 2020 Trial primary completion date: Nov 2015 --> Apr 2017 | Trial completion date: Nov 2015 --> Apr 2017
- | Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
New P2 trial, Surgery: RadioCoBRIM: Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases (clinicaltrials.gov) - Feb 13, 2018
P2, N=32, Not yet recruiting, Sponsor: Technische Universit
- | Gazyva (obinutuzumab) / Roche, Biogen, Zelboraf (vemurafenib) / Roche
Enrollment open: A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia (clinicaltrials.gov) - Feb 12, 2018
P2, N=28, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Nov 2015 --> Apr 2017 | Trial completion date: Nov 2015 --> Apr 2017 Not yet recruiting --> Recruiting
- | ONCase (recombinant methionine α, γ-lyase) / AntiCancer, Shionogi, Nantong Jinghua
Journal: Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models. (Pubmed Central) - Feb 11, 2018
Melanoma patients with the BRAF-V600E mutation have been treated with the drug vemurafenib (VEM) which targets this mutation...Forty BRAF-V600E-negative melanoma PDOX mouse models were randomized into four groups of 10 mice each: untreated control (n = 10); temozolomide (TEM) (25 mg/kg, p.o., 14 consecutive days, n = 10); rMETase (100 units, i.p., 14 consecutive days, n = 10); TEM + rMETase (TEM: 25 mg/kg, p.o., rMETase: 100 units, i.p., 14 consecutive days, n = 10)...The present study shows that TEM combined with rMETase is effective for BRAF-V600E-negative melanoma PDOX similar to the BRAF-V600E-positive mutation melanoma. These results suggest rMETase in combination with first-line chemotherapy can be highly effective in both BRAF-V600E-negative as well as BRAF-V600E-positive melanoma and has clinical potential for this recalcitrant disease.
- | Zelboraf (vemurafenib) / Roche
Clinical, Journal: A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma. (Pubmed Central) - Feb 9, 2018
Coadministration of vemurafenib and TILs was safe and feasible and generated objective clinical responses in this small pilot clinical trial. Clin Cancer Res; 23(2); 351-62.
- | Zelboraf (vemurafenib) / Roche
Journal: Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors. (Pubmed Central) - Feb 7, 2018
Patients with resistance had favorable clinical responses when chloroquine was added to vemurafenib. This provides a fundamentally different strategy to circumvent multiple mechanisms of kinase inhibitor resistance that could be rapidly tested in clinical trials in patients with BRAF(V600E) brain tumors.
- || Zelboraf (vemurafenib) / Roche
Trial primary completion date, Metastases: An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma (clinicaltrials.gov) - Jan 31, 2018
P4, N=60, Active, not recruiting, Sponsor: Hoffmann-La Roche
This provides a fundamentally different strategy to circumvent multiple mechanisms of kinase inhibitor resistance that could be rapidly tested in clinical trials in patients with BRAF(V600E) brain tumors. Trial primary completion date: Dec 2018 --> Dec 2019
- |||| Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche, Tecentriq (atezolizumab) / Roche
Trial primary completion date, PD(L)-1 Biomarker, Metastases: IMspire150: A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma (clinicaltrials.gov) - Jan 31, 2018
P3, N=500, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Dec 2018 --> Dec 2019 Trial primary completion date: Nov 2019 --> Jul 2019
- | Gazyva (obinutuzumab) / Roche, Biogen, Zelboraf (vemurafenib) / Roche
New P2 trial: A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia (clinicaltrials.gov) - Jan 24, 2018
P2, N=28, Not yet recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- | Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Trial primary completion date: CONVERCE: Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis (clinicaltrials.gov) - Jan 19, 2018
P2, N=137, Recruiting, Sponsor: Center Eugene Marquis
Trial primary completion date: Nov 2019 --> Jul 2019 Trial primary completion date: Feb 2018 --> Feb 2019
- || Zelboraf (vemurafenib) / Roche
Trial primary completion date: Safety Study of PLX4032 in Patients With Solid Tumors (clinicaltrials.gov) - Dec 30, 2017
P1, N=75, Active, not recruiting, Sponsor: Plexxikon
Trial primary completion date: Feb 2018 --> Feb 2019 Trial primary completion date: Jun 2014 --> Aug 2015
- | Zelboraf (vemurafenib) / Roche
Journal: Tumor-targeting Salmonella typhimurium A1-R Sensitizes Melanoma with a BRAF-V600E Mutation to Vemurafenib in a Patient-derived Orthotopic Xenograft (PDOX) Nude Mouse Model. (Pubmed Central) - Dec 29, 2017
First-line therapy temozolomide (TEM) could slow but not arrest tumor growth or cause regression...The present study used this PDOX model of melanoma to test its sensitivity to VEM combined with S. typhimurium A1-R compared to VEM alone and VEM combined with COB. VEM combined with S. typhimurium A1-R was significantly more effective than VEM alone or VEM combined with COB (p = 0.0216) which is currently first line therapy for advanced melanoma with BRAF-V600E mutation.
- sonolisib (PX 866) / Pfizer
Enrollment change, Metastases: Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma (clinicaltrials.gov) - Dec 29, 2017
P1/2, N=24, Terminated, Sponsor: Oncothyreon Inc.
VEM combined with S. typhimurium A1-R was significantly more effective than VEM alone or VEM combined with COB (p = 0.0216) which is currently first line therapy for advanced melanoma with BRAF-V600E mutation. N=146 --> 24
- Avastin (bevacizumab) / Roche, Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Enrollment change, Trial termination, Metastases: Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma (clinicaltrials.gov) - Dec 29, 2017
P2, N=10, Terminated, Sponsor: Melanoma Research Foundation Breakthrough Consortium
N=146 --> 24 N=162 --> 10 | Recruiting --> Terminated; Slow accrual; toxicity; change in priorities
- ||||| Zelboraf (vemurafenib) / Roche
Enrollment closed, Metastases: A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3) (clinicaltrials.gov) - Dec 29, 2017
P3, N=677, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=162 --> 10 | Recruiting --> Terminated; Slow accrual; toxicity; change in priorities Recruiting --> Active, not recruiting
- ||||| Zelboraf (vemurafenib) / Roche
New P2 trial, Metastases: The Safety and Efficacy Study of Vemurafenib (CT) Compared With Vemurafenib (Zelbolaf (clinicaltrials.gov) - Dec 25, 2017
P2, N=100, Recruiting, Sponsor: Cancer Centre of Monoclonal Therapy, LLC
- | Zelboraf (vemurafenib) / Roche
Clinical, P2 data, Journal: Vemurafenib in Metastatic Melanoma Patients with Brain Metastases: An Open-Label, Single-Arm, Phase 2, Multicentre Study. (Pubmed Central) - Dec 25, 2017
Recruiting --> Active, not recruiting The study demonstrates clinically meaningful response rates of melanoma BM to vemurafenib that was well tolerated and without significant CNS toxicity.
- |||||||||| Zelboraf (vemurafenib) / Roche
New P3 trial, Metastases: A Study of Vemurafenib in Participants With Metastatic Melanoma (clinicaltrials.gov) - Dec 19, 2017
P3, N=3219, Completed, Sponsor: Hoffmann-La Roche
- Zelboraf (vemurafenib) / Roche
Trial completion: A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants (clinicaltrials.gov) - Dec 18, 2017
P1, N=8, Completed, Sponsor: Hoffmann-La Roche
The study demonstrates clinically meaningful response rates of melanoma BM to vemurafenib that was well tolerated and without significant CNS toxicity. Active, not recruiting --> Completed
- | Zelboraf (vemurafenib) / Roche
Journal: Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors. (Pubmed Central) - Nov 30, 2017
BRAF inhibitor vemurafenib was recently found to demonstrate activity across various BRAF-mutated nonmelanoma cancer types...PI3K-mTOR pathway aberrations were associated with a statistically significant reduction in progression-free survival (HR = 15.0, 95% CI = 3.6 to 63.0, P < .001) and overall survival (HR = 19.2, 95% CI = 3.7 to 100.0, P < .001). This suggests that co-occurring genomic alterations may predict response and resistance to BRAF inhibitor therapy and identify subgroups of BRAF-mutated nonmelanomas cancers.
- | Zelboraf (vemurafenib) / Roche
Journal: Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study. (Pubmed Central) - Nov 29, 2017
The combination of oral vemurafenib with subcutaneous decitabine is safe and showed activity in V600EBRAF positive metastatic melanoma. Since most responses were seen in cohort 1, which utilized low-dose, long-term decitabine, future studies of this combination treatment should utilize longer duration of decitabine, at the lowest dose of 0.1 mg/kg.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Zelboraf (vemurafenib) / Roche
Journal: Phase 1B Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation. (Pubmed Central) - Oct 28, 2017
cfDNA predicted radiographic response and identified mutations reactivating the MAPK pathway upon progression. Cancer Discov; 6(12); 1352-65.
- | Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche, Tecentriq (atezolizumab) / Roche
Biomarker, Trial primary completion date, PD(L)-1 Biomarker: Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC (clinicaltrials.gov) - Oct 27, 2017
P2, N=110, Recruiting, Sponsor: University Hospital Tuebingen
Cancer Discov; 6(12); 1352-65. Trial primary completion date: Apr 2017 --> Apr 2019
- | Zelboraf (vemurafenib) / Roche
Trial primary completion date: Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma (clinicaltrials.gov) - Oct 25, 2017
P2, N=17, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Apr 2017 --> Apr 2019 Trial primary completion date: Mar 2018 --> Aug 2018
- |||||| Enrollment open, Tumor mutational burden, IO Companion diagnostic, PD(L)-1 Biomarker, PD(L)-1 companion diagnostic, Metastases: BFAST: A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Oct 10, 2017
P2/3, N=580, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2018 --> Aug 2018 Not yet recruiting --> Recruiting
- ||||| New P2 trial, Tumor mutational burden, BRCA Biomarker, PARP Biomarker, PD(L)-1 Biomarker: Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (clinicaltrials.gov) - Sep 28, 2017
P2, N=720, Not yet recruiting, Sponsor: Canadian Cancer Trials Group
- | Trial primary completion date: MetAction: N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy (clinicaltrials.gov) - Sep 27, 2017
P2, N=50, Active, not recruiting, Sponsor: Oslo University Hospital
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2017 --> Aug 2018
- Erbitux (cetuximab) / Eli Lilly, Zelboraf (vemurafenib) / Roche
Enrollment closed, Enrollment change, Combination therapy, Surgery, Metastases: Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery (clinicaltrials.gov) - Sep 21, 2017
P1, N=47, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Aug 2017 --> Aug 2018 Recruiting --> Active, not recruiting | N=35 --> 47
- buparlisib (AN2025) / Novartis, Adlai Nortye, Zelboraf (vemurafenib) / Roche
Trial completion, Enrollment change, Trial primary completion date, Metastases: BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma (clinicaltrials.gov) - Sep 18, 2017
P1/2, N=8, Completed, Sponsor: University of California, San Francisco
Recruiting --> Active, not recruiting | N=35 --> 47 Recruiting --> Completed | N=46 --> 8 | Trial primary completion date: Jun 2014 --> Dec 2013
- ||| Biomarker, Enrollment change, Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Sep 1, 2017
P2, N=1400, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Completed | N=46 --> 8 | Trial primary completion date: Jun 2014 --> Dec 2013 N=610 --> 1400 | Trial primary completion date: Feb 2019 --> Oct 2020
- ||| Zelboraf (vemurafenib) / Roche
Trial completion, Enrollment change: Safety Study of PLX4032 in Patients With Solid Tumors (clinicaltrials.gov) - Aug 22, 2017
P1, N=109, Completed, Sponsor: Plexxikon
N=610 --> 1400 | Trial primary completion date: Feb 2019 --> Oct 2020 Active, not recruiting --> Completed | N=75 --> 109
- | Zelboraf (vemurafenib) / Roche
Enrollment closed, Metastases: Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer (clinicaltrials.gov) - Aug 22, 2017
P2, N=24, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | N=75 --> 109 Recruiting --> Active, not recruiting
- | Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Enrollment open: Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma (clinicaltrials.gov) - Aug 6, 2017
P2, N=36, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Tecentriq (atezolizumab) / Roche
Enrollment open, PD(L)-1 Biomarker: Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer (clinicaltrials.gov) - Aug 6, 2017
P2, N=50, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Trial primary completion date, Metastases: Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib (clinicaltrials.gov) - Aug 4, 2017
P1/2, N=38, Recruiting, Sponsor: University of Iowa
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2017 --> Jun 2018
- | New P2 trial: Efficacy and Safety of Precision Therapy in Refractory Tumor (clinicaltrials.gov) - Aug 2, 2017
P2, N=60, Recruiting, Sponsor: Baodong Qin
- ||| Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Enrollment change, Trial primary completion date, Metastases: A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma (clinicaltrials.gov) - Aug 2, 2017
P2, N=52, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jun 2017 --> Jun 2018 N=208 --> 52 | Trial primary completion date: May 2021 --> Dec 2017
- || Cotellic (cobimetinib) / Exelixis, Roche
Enrollment closed, Metastases: MELANIS: A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic (clinicaltrials.gov) - Jul 31, 2017
P=N/A, N=200, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=208 --> 52 | Trial primary completion date: May 2021 --> Dec 2017 Recruiting --> Active, not recruiting
- | Biomarker, Enrollment open, BRCA Biomarker, PARP Biomarker, Metastases: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (clinicaltrials.gov) - Jul 28, 2017
P2, N=1500, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Zelboraf (vemurafenib) / Roche
Biomarker, Enrollment open, Metastases: Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) (clinicaltrials.gov) - Jul 27, 2017
P2, N=49, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting